Karyopharm

#药闻简讯# $Karyopharm(KPTI)$ 宣布战略融资交易以支持业务增长；将现金储备延长至2026年第二季度，超出骨髓纤维化三期SENTRY试验预期关键数据公布时间

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-25-241484  Size: 4 KB 网页链接

$Karyopharm(KPTI)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001193125-25-262581  Act: 33  Size: 520 KB 网页链接

$Karyopharm(KPTI)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001493152-25-020601  Act: 34  Size: 9 KB 网页链接

$Karyopharm(KPTI)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001897612-25-000507  Act: 34  Size: 7 KB 网页链接

$Karyopharm(KPTI)$ 大跌12%。虽然交易量不算大。
融资。解决短期债务问题。
没办法，必须需要新的Asset才能变现。

$Karyopharm(KPTI)$ 8-K Current report, items 1.01, 2.02, 2.03, 3.02, 5.02, 7.01, 8.01, and 9.01 Accession Number: 0001193125-25-233983  Act: 34  Size: 282 KB 网页链接

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-25-230359  Size: 5 KB 网页链接

$Karyopharm(KPTI)$ SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors Accession Number: 0001493152-25-018449  Act: 34  Size: 23 KB 网页链接

$Karyopharm(KPTI)$ 8-K Current report, items 1.01, 2.03, 8.01, and 9.01 Accession Number: 0001193125-25-239015  Act: 34  Size: 6 MB 网页链接

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-25-241487  Size: 4 KB 网页链接

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-25-241471  Size: 4 KB 网页链接

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-25-241461  Size: 5 KB 网页链接

$Karyopharm(KPTI)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001193125-25-291930  Act: 33  Size: 299 KB 网页链接

$Karyopharm(KPTI)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-25-261663  Act: 34  Size: 518 KB 网页链接

$Karyopharm(KPTI)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001193125-25-261667  Act: 34  Size: 12 MB 网页链接

$Karyopharm(KPTI)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001193125-25-262571  Act: 33  Size: 557 KB 网页链接

$Karyopharm(KPTI)$ Opaleye Management Inc. 与 Opaleye, L.P. 以及 James Silverman 于 2025年10月17日 向美国证券交易委员会（SEC）提交了 Schedule 13G 文件，披露他们实益持有 Karyopharm Therapeutics Inc. 的普通股共计 1,569,002 股，占公司已发行股份的 9.48%。
其中包括 619,089 股...

$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001193125-25-241479  Size: 4 KB 网页链接

$Karyopharm(KPTI)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000102909-25-000154  Act: 34  Size: 6 KB 网页链接